1265
www.dermatologiepropraxi.cz451480430107651332012142633073344084494765225425906406597037527798268779039459851004102010601099
341838026012657115
PŘEHLEDOVÉ341207012660124182256312369444520587645
ČLÁNKY1008207012660115187259327395
Mechanismy34136501065284118160199241258290344380
rezistence73736501063366100118150183215256291323
na107636501063979
imunoterapii117036501061669110151192222255291332367384401
melanomu158736501065284115157198239293333
DERMATOLOGIE3418043010758102149221276314375417477536557600
PRO963804301074591154
PRAXI1138804301074591148201221
23.340553085357185
Ni4375540834458
K,5075540833448
O’Neill5675540834659103137152166180
H.7595540834356
The8275540833270104
role943554083205671105
of10605540833655
dendritic11275540833771108146166181203217248
cells138755408330637892117
in15165540831551
T157955408332
cell162355408331637892
activation.1727554083316386100132164185199236273286
Immunol3406540831571128165202240255
Cell608654083397287102
Biol.722654083355087103115
1997;75(3):223-230.850654083336398130139171203221254270282316350384406436470504516
doi:10.1038/icb.1997.35.1378654083387590102131162174204235268301326342373411423454483518550556591623634
24.340753085367187
Wu4487540835895
W,5647540835767
Wang6527540835889128167
W,8407540835767
Wang9287540835889128167
Y,11167540833544
et11807540833457
al.1258754083324760
IL-37b133975408315476295127166
suppresses15267540832664103143165199226253289316
T186275408333
cell191675408331658196
priming340854083396076134149187226
by5828540833970
modulating6688540835896136173188221242258296335
dendritic10198540833873111150171187209225257
cell129285408331658095
maturation14048540835790111149170203225240278317
and17378540833270109
cytokine1863854083316489126340954083304684119
production477954083396097137175207231246284323
via818954083314779
dampening9159540833871128168203241256294333
ERK/NF-κB/S6K12669540833368104133179212233267303328361396431
signalings.1715954083274180118150166181219258284297
Acta34010540834275100134
Biochim4951054083375392126165181241
Biophys7571054083375392133173205233
Sin10111054083344988
(Shanghai).11211054083195291125164204244277293313325
2015;47(8):597-603.146710540833570103135146182215233267286299336369403423461498532545
doi:10.1093/abbs/gmv058.3401154083387692104134165178208240275308332362402441468494529587619655689723737
25.3401253085357084
Lindenberg4341254083314581119152188226260280316
JJ,7611254083244657
van8291254083316298
de93812540833871
Ven102012540833566102
R,113312540833548
Lougheed119112540833167103141177210244282
SM,14841254083328496
et159112540833354
al.16561254083314557
Functional172412540833266103133156170206243274288
characterization34013540833168100120153184207240261276304337358372409447
of79913540833755
a866135408332
STAT3-dependent90913540833366103131166187227261299334371410444481502
dendritic142213540833873110148169183205220251
cell-derived1684135408332657994115155189209224256290328
CD1434014540834085115146
+500145408342
cell557145408331647993
population66514540833977116153168199220235272310
arising990145408331526792106143182
upon118614540833876114152
IL-10-driven1353145408314456090121144184204219251284322
maturation.168914540835889110148168200221236273311324
Oncoimmunology.34015540834785116153167224281318356393409446485516525
2013;2(4):e23837.8791554083356899128139173190222239250284318352385419450455
doi:10.4161/onci.23837.13481554083387691102131162174207237268297318352390422436448484518551585616622
26.3401653085367187
Emeagi44416540833390125157196211
PU,6721654083357889
Maenhout77716540835587122160199237275297
S,109116540833245
Dang115216540834678116155
N,132316540834558
et139716540833456
al.14701654083314760
Downregulation154616540834584135174195229268306321353375391428467
of34017540833756
Stat34091754083325385107142
in56417540831452
melanoma:62817540835792107139177215273305317
Reprogramming95717540833570109130167206227260317374389427465
the14351754083225994
immune154217540831472129166204238
microenvironment1793175408357721041251611973401854083376883103140178234269306327
as67918540833157
an74918540833168
anticancer8291854083326990105136168205237270290
therapeutic11321854083215893113146184219256278292324
strategy.14681854083264869101123156194226235
Gene171518540834478116150
Ther.187718540833271105126135
2013;20(11):1085-1092.34019540833468100130141176210230262289304316345377412446468499531566599611
doi:10.1038/gt.2013.35.9671954083387692104133165177208240273307332368391404440474506536548584617629
27.3402053085357078
Hong43120540834481119157
M,60020540835467
Puaux68020540833471102139170
AL,8622054083417285
Huang95920540834481113150188
C,116020540833951
et122420540833355
al.12912054083324759
Chemotherapy136320540833976110167205226264298319351389420
induces17952054083155290127159192218
intratumoral340215408314517292124145182238275296327342
expression69421540833364102122155181207221258295
of100121540833655
chemokines106721540833168101158195224240277310336
in141521540831451
cutaneous14782154083306789120157191228265290
melanoma,17802154083569010513617321034022540835789102
favoring4542254083185183120141156194233
T-cell6992254083335184117133147
infiltration859225408315526986101123144177198213251289
and116022540833270108
tumor128122540832159116154175
control.146922540833168106127148185201213
Cancer169522540833972110141175196
Res.19032254083357096110
2011;71(22):6997-7009.34023540833468100128136169201216250285303315350384419452471502535571607618
doi:10.1158/0008-5472.CAN-11-1466.97323540833876921041331651782082362663003253593954314674905245595916256386777207657888198468658969279639991012
28.3402453085377592
Harlin45424540834579101118134174
H,64924540834660
Meng73124540835692132173
Y,92524540833746
Peterson9932454083367194129152180220260
AC,12752454083428397
et139424540833558
al.14742454083334963
Chemokine155924540834180117177217249266306342
expression1923245408335683402554083406398127155170210250
in61425540831555
melanoma69325540835996112146186226287321
metastases103725540835996120154182207241269306334
associated13952554083326088128163179212235271312
with17312554083526992132
CD8188725540834189125
+340265408343
T-CeII4082654083345398134151167
recruitment.6002654083215792114154171195255292332355369
Cancer99526540834175115149184207
Res.122726540833773102117
2009;69(7):3077-3085.136926540833571109146160197233253290310323360397431467487521558595631644
doi:10.1158/0008-5472.CAN-08-2281.340275408338769210413416517820823626630032635939543246749052455959162563867772076578882586188391494998310151024
29.3402853085367285
Yue44428540833570105
C,56828540834053
Shen64028540833270105143
S,80228540833245
Deng86628540834581119158
J,104328540832436
et109828540833456
al.11732854083324760
STAT3125228540833267104133168
in143928540831553
CD8+151128540833985120163
T1692285408333
cells1744285408331658095121
inhibits188428540831553911063402954083395477105
their4652954083226095110132
tumor61729540832260118156178
accumulation8152954083326596133191229245277299314352391
by122629540833970
downregulating131729540833876127166187222261299314347368384422461
CXCR3/179829540834080119155190215
CXCL1034030540834184125159191225
axis.5993054083336784113128
Cancer76230540834176117151187211
Immunol100730540831576137177218259277
Res.131830540833774103119
2015;3(8):864-870.147130540833572106138151188209245265278316354393418456492527541
doi:10.1158/2326-6066.CIR-15-0014.3403154083387692104134165178208236266300326360395428461485522558593629642682697733755785815838875911943974986
30.3403253085367288
Kučera44832540833572104138159192
J,66132540832436
Strnadová7173254083335476114147186224256289
K,102732540833549
Dvořánková109732540834579116138171209239277309342
B,145932540833648
et152832540833456
al.16053254083324760
Serum16853254083336889128186
proteomic189132540833960983403354083225694153168200
analysis56133540833170102117149176191217
of79933540833757
melanoma87633540835893108141179217276308
patients12053354083387193109143182203231
with14573354083506688127
immunohistochemical16043354083157313116820724528429932534838534034540833169104162177209242257
profiling6163454083386097115132147162200239
of87334540833857
primary9483454083396076134166187221
melanomas118834540835792108140178216274307333
and154034540833169108
cultured16673454083316984107144166200239
cells:192534540833164340355408315305668
Pilot4243554083354965103125
study.5643554083264987126158168
Oncol74835540834785117154170
Rep.93335540833671110123
2019;42(5):1793-1804.107135540833468100130143178210228261279291321351384417439469500536572585
doi:10.3892/16713554083387692104133165177213247282315341
or.2019.7319.3403654083375969105139171201212246281311342353
31.3403753085367083
Bouzin43837540833574113143160198
C,65137540834054
Brouet7203754083355795134170193
A,92837540834155
De99937540834581
Vriese10953754083365773108136172
J,128237540832436
et133437540833356
al140637540833147
O.146837540834760
Effects15433754083325271106140164193
of175137540833757
Vascular182337540833668951281663403854083154870
Endothelial43238540833271111150173212248264280312329
Growth78338540834366104156181220
Factor10253854083336396121159181
on122838540833777
the13263854083226197
Lymphocyte-Endothelium1445385408331611201602002392723063323673914264645045433403954083226096112127165224
Interactions:5783954083155375110131165198222238277316342355
Identification9483954083145489128150166184201234267289305344383
of134539540833757
Caveolin-1141639540834073105140179196211250273304
and173439540833271110
Nitric18583954083456184106122154
Oxide3404054083477995134170
as52440540833259
Control59740540834077116139161198215
Points8264054083357288127149177
of101740540833757
Endothelial108940540833270110149171210245261277309325
Cell14294054083397490106
Anergy.154940540834179115137175208219
J1782405408324
Immunol.1820405408315731311703404154083377692105
2007;178(3):1505-1511.45941540833468105137148178208241261294312324354384419453475507537568596606
doi:10.4049/jimmunol.178.3.1505.10794154083377692104134166179213249286319343359375433490528566605621634665695729743778791822852887921933
32.3404253085377390
Huang45242540834585119158199
H,67342540834559
Langenkamp75442540833368107148184224256291351392
E,116842540833347
Georganaki123842540834582122145184218258292323341
M,160142540835670
et169342540833559
al.17744254083334963
VEGF185942540833772118153
suppresses34043540832662101139160194220246280306
T-lymphocyte658435408332506697155193231268300333357390
infiltration1060435408315526986100122143175196211248286
in135843540831552
the14224354083215993
tumor152743540832259115153174
microenvironment1713435408357711031231601952322632783404454083205794150185222242
through5944454083225979115153191228
inhibition8344454083145188102140155177192229266
of111244540833755
NF-κB-induced11794454083447697129165187202239277314345378416
endothelial160744540833370108146167204238253267298313
activation.1932445408331633404554083213669101123138175213226
FASEB57945540833269103135170
J.76145540832437
2015;29(1):227-238.8104554083346899129139174208226258272283318353385403434468502515
doi:10.1096/fj.14-250985.13384554083387691103132163175206237272307331349365377408438461492526560595629663674
33.3404653085367288
Chen44946540834079115154
PL,6244654083356781
Roh72646540833675115
W,86246540835868
Reuben95146540833672110150187225
A,119846540834156
et127546540833457
al.13534654083324861
Analysis143546540834281114130162190205232
of168846540833858
immune176746540831573132171210245
signatures3404754083264180118150172210231265292
in64747540831552
longitudinal7154754083145391130145168206245260298330345
tumor107547540832260118156178
samples126847540832659117156172207234
yields1517475408331468197136162
insight1694475408315527994132170192
into19014754083155374111
biomarkers3404854083385491149181201232265286313
of66548540833756
response7344854083205480119157195221256
and100248540833269108
mechanisms112248540835792124161193231246271328354
of148948540833756
resistance1557485408321548195121144176214245278
to184848540832158
immune19184854083157234049540835693129163
check-point51549540833167101133162181220257272309329
blockade.8564954083385390122151183221255266
Cancer113449540833971107138171191
Discov.13374954083445984115151182191
2016;6(8):827-837.15404954083346697127139173192224241252286319350368403436467472
doi:10.1158/2159-8290.CD-15-1545.3405054083387692104134165178208236266300326360392422454478514547581617630669715739769799822852882918950962
34.3405153085367388
Ott4465154083477195
PA,5585154083357287
Stephen6625154083325387126165200238
Hodi91751540834482122137
F,107151540833238
Buchbinder112651540833674106144183199236275310332
EI.14755154083324760
Inhibition15535154083145290105144160183198236274
of184451540833857
immune19185154083157234052540835693130164
check-points51652540833168102133163182221259274311331358
and88652540833168106
vascular10045254083326489121157172203224
endothelial124052540833370108145166204238253267298313
growth15655254083375794144167205
factor17815254083195182106141162
as195552540833257
combination34053540833167125164179216248269284322360
therapy7125354083225994115147186216
for9415354083185576
metastatic103053540835791113145172194227248263294
melanoma:133753540835791107138176214271303315
An166453540834179
overview175553540833769102123157173207257
of34054540833755
rationale,407545408321537488125163194209243254
preclinical6735454083385992124139153190204235267282
evidence,9675454083346580118152189220253264
and124354540833269107
initial1362545408314516687102133148
clinical1522545408331456096111142174189
data.17235454083376990121134
Front18675454083325187125145
Oncol.34055540834786118155171184
2015;5(SEP).53955540833468100130141176193225257293310321
doi:10.3389/fonc.2015.00202.8765554083387691104133165177213246280315338357395433465479515549581611623658694727761794806
35.3405653085367186
Restifo4465654083357097120136155193
NP,6595654083458085
Smyth76456540833390121146184
MJ,9685654083558193
Snyder108156540833370101139174196
A.129756540834156
Acquired137356540834172110148163184218258
resistance1651565408321558296123146178217249282
to195456540832158
immunotherapy34057540831575135174214254277317353376410451484
and84657540833372113
future9825754083185983122144180
challenges.118457540833372106122138175214255292320334
Nat154157540834679102
Rev166657540833673106
Cancer.179557540834175115148184206217
2016;16(2):121-126.34058540833468100131143174205224258276287317347379397428458492505
doi:10.1038/nrc.2016.2.8605854083387692104134165178209240273308333369390421435471505537568581617630
36.3405953085367288
Restifo4455954083357097120136155193
NP,6545954083458185
Marincola75659540835587108124162194231247279
FM,10525954083328599
Kawakami116859540833468119152182215273288
Y,147359540833544
et153359540833457
al.16065954083324860
Loss16835954083326996122
of182259540833757
functional189559540831957953406054083315571109147179195
beta2-microglobulin5496054083387496129163184242258289311348388403441481519534549587
in115060540831452
metastatic121660540835793115148174197230252267299
melanomas152960540835792108140178217275307334
from18776054083184077136
five3406154083173467101
patients4626154083397294109144182204232
receiving7156154083205588122137170185224263
immunotherapy.99861540831573131169207246268306342363396436467477
J1496615408324
Natl15416154083457799115
Cancer167661540834073112144178199
Inst.18966154083155380103116
1996;88(2):100-108.34062540833464100135147183218237271289301331362398422453484520533
doi:10.1093/jnci/88.2.100.8886254083397792104134165178209240275308332349387419434460494529543579591622653689702
37.3406353085367079
Del4326354083458196
Campo54163540834073130170208
AB,7626354083417790
Kyte8656354083346488122
JA,10006354083246478
Carretero10916354083407394116150172205227264
J,136863540832436
et141763540833456
al.14866354083324760
Immune155963540831572130168206241
escape18136354083346092125164200
of34064540833757
cancer41164540833264102135168189
cells615645408331658196122
with7526454083506688126
beta2-microglobulin8936454083397497129164184243258290311349388403441481519535550587
loss14956454083155380106
over161664540833869104125
the17566454083216095
course18656454083326810712821405540832661
of22155540833757
metastatic22865540835792114147174197229251267298
melanoma.25985540835893108141179217275308321
Int2933554083155374
J302155408324
Cancer.30595540834073111143177198208
2014;134(1):102-113.32815540833468100131143173203239258290304316346377410431461489519531
doi:10.1002/ijc.28338.2140654083387692104134165178208240276309335351367399412448482516549583596
38.2140753085357085
Zaretsky2235754083376888121142168196228
JM,2474754083247789
Garcia-Diaz2573754083437494124137168189234248279307
A,28907540834153
Shin2954754083326882118
DS,3083754083447587
et31817540833354
al.3245754083324657
Mutations33137540835490111142162176213249274
associated35987540833156811181491631932140854083215492
with2243854083506586123
acquired2377854083316299135149169202240
resistance262885408321547993118140172208239272
to29118540832157
PD-129798540833578101130
blockade3120854083395490122151183221254
in33858540831551
melanoma.34478540835791106137173210267298310
N376885408345
Engl21409540833370108123
J227495408324
Med.23109540835489127140
2016;375(9):819-829.2462954083346798129140174206238255286304315349380410432468501534544
doi:10.1056/NEJMoa1604958.3018954083387590101130161173203234267301325370403429483520553582612647682715748782794
39.21401053085367185
Jin22441054083243977
W.234010540835767
Role24261054083367490125
of257010540833756
JAK/STAT3264510540832464100128161196233262297
Signaling29611054083334886124157172187225264
in324410540831452
the33151054083226095
Regulation342910540833570110147163195217232270308
of375610540833857
Metastasis,214011540835490112145171194227254268295308
the24611154083226095
Transition25701154083325083121147162184200238276
of286011540833756
Cancer293011540834073111143177198
Stem31421154083325387145
Cells,33011154083397389104130143
and345811540833169109
Chemoresistance3580115408340781131712092140125408321558296122146178216249282
of243912540833756
Cancer251112540834073111143177198
by272512540833970
Epithelial–Mesenchymal28121254083327187109147182198213245260297353388415450488520558589647680695
Transition.35231254083335083121147162185200238276290
Cells.21401354083407489104130144
2020;9(1):217.229913540833469101136148184203235249261296328357363
doi:10.3390/cells9010217.26781354083387691103133165177213246279315339368402417432458493529560592625656686692
40.21401453085377693
Karachaliou22571454083367194128162202236252268308348
N,262914540834660
Gonzalez-Cao271214540834586126157192209245276299344378418
M,315414540835671
Crespo32491454083416399127168208
G,348114540834560
et356514540833558
al.36471454083335063
Interferon3734145408316552140155408322567899134156194233
gamma,239415540833871129188221234
an264915540833270
important274015540831574113153175200233271293
marker305415540835891112143178200
of327515540833757
response33531554083215582122161200227262
to363615540832260
immune371615540831574214016540835998138174
check-point233616540833272109143174196237278294334356
blockade27141654083405796131162197238274
in301016540831555
non-small308616540833979119143171231264281297
cell34051654083326784100
lung35261654083165594135
cancer36831654083326610621401754083316586
and224617540833169109
melanoma237417540835792108140178217275307
patients.27011754083387193108143181203230244
Ther296517540833271106128
Adv311217540834179112
Med324417540835489129
Oncol.339217540834786118155171184
2018;10.359517540833468100131143174205218
doi:10.1177/1758834017749748.21401854083387692104134165178208236265300320353382415449485519554590622651686716749782813849862
41.21401953085366981
Kim223719540833551109
TK,23621954083336984
Herbst246319540834479100140166190
RS,26691954083356982
Chen276719540834078113151
L.293519540833145
Defining29961954083468199116153169206245
and325819540833270109
Understanding338319540834482121156177204227260298337352390429
Adaptive214020540834077108146168182214247
Resistance23982054083356995109134156188225256288
in269820540831451
Cancer276120540833971108139171192
Immunotherapy.296420540831571127164200238259295329350382419450459
Trends34352054083324881118156181
Immunol.36282054083147112716321402154083387692105
2018;39(8):624-631.226021540833468100131143178211231264282294330363395418455489520529
doi:10.1016/j.it.2018.05.001.28042154083397792104134166178209240272303328345358373396409445479511542556591625637672708740749
42.21402253085367086
Koyama224522540833572104137194227
S,249122540833245
Akbay255522540834171112145175
EA,27492254083337690
Li285822540833147
YY,29232254083367483
et302422540833457
al.31002254083314760
Adaptive317922540834179111150172188220255
resistance3453225408320548196122145178216248282
to375422540832158
therapeutic21402354083226095116149188224261284299331
PD-1248923540833580104135
blockade26422354083395593125155189228263
is292323540831441
associated29822354083315884123155171203224258298
with32982354083506688126
upregulation34422354083377798132172209225257279294332370
of214024540833757
alternative22172454083324870104125164197219234267301
immune253924540831472130168206242
check-points.280124540833170105138168188228267283321343371384
Nat32062454083457799
Commun.332624540834077135193231269283
2016;7.362924540833569101132144177184
doi:10.1038/ncomms10501.21402554083387692104134165178208240273307333369401438496554581611642676710742752
43.21402653085367186
Taube22462654083336198137173
JM,24392654083247992
Young255126540833569107145184
GD,275526540834490101
McMiller287626540835487142157173188222244
TL,31402654083326579
et323926540833356
al.33152654083314760
Differential3395265408345608099134155189227248264296311
expression37262654083346621402754083386093120146160198236
of238827540833756
immune-regulatory245727540831471128165203237260282315354392407438460496517551
genes302027540833873110145171
associated32042754083315784121154168200221255294
with35102754083506588125
PD-L1364827540833579102135164
display21402854083385379118134166197
in235028540831452
melanoma:241528540835792108140178216274306319
Implications274728540831472111127142174207228243281320346
for31062854083185677
PD-1319628540833580104135
pathway33442854083387193131181214245
blockade.3602285408338549212515518821402954083387385
Clin22402954083395570107
Cancer236229540834073111143177198
Res.25742954083357097111
2015;21(17):3969-3976.269929540833469100130141176208223254284303315350384419453476509542575607620
doi:10.1158/10780432.CCR-15-0244.33342954083387691103133165177208236266300325358390422456214030540833470103136148188226261283314344366403436468505518
44.21403153085367388
Vétizou22393154083356789103131167204
M,245531540835466
Pitt2533315408334487093
JM,26373154083247891
Daillère27393154083457690105119153173206
R,295631540833548
et301631540833355
al.30823154083324658
Anticancer31513154083417899113144176213244277297
immunotherapy34603154083147112716420123825929633021403254083205290120
by227132540833969
CTLA-4235132540833974106148168203
blockade25653254083395491122151183221255
relies2831325408320536882115141
on298332540833774
the30683254083225992
gut31713254083387596
microbiota.327832540835771102122158196211248268300312
Science36013254083336478111148179211
(80-21403354083195186109
).226333540831929
2015;350(6264):1079-1084.23063354083346799128138172205238257289322355391407419448478510543566596627662697709
doi:10.1126/science.aad1329.30293354083387590102131161173203230260292317341372386420458489522534567598637668697729762773
45.21403453085367185
Sivan22383454083324779111149
A,239934540834154
Corrales24663454083397697118151166200227
L,270534540833145
Hubert276234540834481119155175200
N,297434540834457
et304334540833456
al.31113454083324760
Commensal318334540834076134191225263289321336
Bifidobacterium35323454083355067841221601992312632140355408321547590127183
promotes23363554083385995152190211244270
antitumor26183554083326990105126164220258279
immunity290935540831471128165202216238271
and319235540833269107
facilitates3311355408318518297112126148180201234260
anti-PD-35833554083326990105126162206229
-L121403654083215484
efficacy.2243365408334527088120153185219229
Science.24913654083336580115153185219231
2015;350(6264):1084-1089.274136540833468100130141176209243263296329363399417429458490525562585615647682717728
doi:10.1126/34883654083387692104134165178208236266299325
science.aac4255.21403754083265873108146178212224258290323355388423455467
46.21403853085367389
Shaikh224238540833270102117147186
FY,24413854083326977
Gills2531385408343597489115
JJ,26583854083244860
Sears27313854083326799120147
CL.28913854083407184
Impact298838540831573111144176200
of320138540833756
the32703854083226094
microbiome337738540835772104125162202217255313348
on373838540833775
check-point214039540833169104137167187227266282319341
inhibitor25003954083145290105144160182219241
treatment27603954083214377109131189224262283
in306239540831553
patients31333954083397294109144182203231
with33833954083506688127
non-small352839540833876115137164222254269284
cell2140405408331658196
lung22494054083155290129
cancer239140540833265103135168190
and259440540833270109
melanoma.271640540835792108140178216275307320
EBioMedicine.30504054083326883121176211251266298313351386398
2019;48:642647.346140540833569101131144178214227262298331214041540833471103109
doi:10.1016/j.ebiom.2019.08.076.22644154083387692104134165178209240272303328344357392431447485543556592626658688699734770783818851883896
47.21404253085367180
McQuade223542540835487137175208248284
JL,25334254083245771
Ologun261942540834764102143181220
GO,285342540834492104
Arora297242540834062100123156
R,314342540833550
Wargo320742540835890112150189
JA.34114254083246480
Gut350542540834483106
Microbiome36254254083557110412616421404354083395593152188
Modulation234243540835594134172188221243259298337
Via26934354083355385
Fecal279343540833266100133149
Microbiota295743540835470103124162202219257280313
Transplant32844354083335184123150190206239278300
to359843540832259
Augment367143540834179119214044540835793132154
Immunotherapy230844540831573132170208247270309344366400439471
in279444540831453
Patients28614454083356890106141180202231
with31064454083506790128
Melanoma324944540835490106139177216275308
or357244540833759
Other364544540834771110146168
Cancers.214045540834176116150185208237252
Curr241545540834179102125
Oncol256345540834889123162179
Rep.276545540833673114128
2020;22(7).291645540833571106142156193230249285306319
doi:10.1007/s11912020-00913-y.32574554083398096110142175189221255293327349375407436468502534214046540833468103127165202238270301324356367
48.21404753085367490
Yang224547540833565103142
M,240147540835568
Wang248447540835889127166
Y,266547540833543
Yuan272347540833570103141
M,287847540835568
et296147540833456
al.30324754083324760
Antibiotic310747540834179101116155170208230246278
administration339947540833271129144182197223246268301323338376414
shortly214048540832663101122146161192
before23444854083397392129150184
or254048540833758
after26104854083325075108128
immunotherapy275148540831471128165202240261299333354386425456
initiation3219485408314526688103134156171208246
is347748540831440
correlated35294854083316788110143158190211244283
with21404954083516689127
poor228249540833877116137
prognosis24344954083396098137175213240255281
in273049540831452
solid2797495408326648095134
cancer294649540833164102134168189
patients:31504954083397293109143181203231243
An340849540834179
up-to-date350249540833776100122159182223255277310
systematic21405054083265884107140197229250265296
review24495054083205485101135185
and264650540833269108
meta-analysis.276650540835791113145167199236268283314341355381394
Int31725054083155273
Immunopharmacol.325850540831471128165202240279317349369427459490526542555
2020;88.214051540833468101135148183219232
doi:10.1016/j.intimp.2020.106876.23875154083397792104134166178209240272303328345358373411433448506545558594628661695707738769805841874906919
49.21405253085367285
Gopalakrishnan224452540834482122155170203233255271297335373405443
V,270652540833645
Spencer277052540833371107145177211232
CN,30225254083398497
Nezi313952540834479109124
L,328352540833145
et334752540833456
al.34235254083324760
Gut350252540834482105
microbiome36265254083577210412616321405354083395594153189
modulates235053540835898138176192225247282309
response26805354083215684123163202229265
to296653540832260
anti-PD-130475354083327193109131169215239271
immunotherapy333953540831573132171210249271310346368401441473
in214054540831553
melanoma220854540835893108140178217275307
patients.25315454083397293109143181203231244
Science27915454083326580115153185218
(80-30255454083195288111
).315254540831930
2018;359(6371):97-103.319754540833569100131144179212244263296330362395409421456489508538570603615
doi:10.1126/science.aan4236.21405554083387692104134165178208236266300325349381396431469501535547581613651687719754788802
50.21405653085367287
Chaput224156540834078110149187210
N,246456540834558
Lepage253556540833165105138177212
P,276056540833540
Coutzac281356540834077115137168202234
C,306056540834053
et312656540833456
al.31965654083314760
Baseline32695654083356895130145160198233
gut35155654083387699
microbiota36275654083577210412616321405754083405696119153
predicts23155754083406298139155189214243
clinical25805754083324864103119153187203
response28055754083215785126166206234270
and309757540833372113
colitis32325754083327087103127143170
in342457540831554
metastatic350057540835996119154181206240263279312
melanoma214058540835894111144183222282315
patients24765854083397396112147186208237
treated27345854083224479112134169210
with29655854083516891130
ipilimumab.3116585408315557187103162200259293333346
Ann348358540834281120
Oncol.362458540834888121159175189
2017;28(6):1368-1379.214059540833468100129139174208227260278290320350384420442473503535569580
doi:10.1093/annonc/mdx108.27355954083387692104134165178208240275308332362400438477515547575631670701733764800813
51.21406053085367082
Matson224160540835487109136175213
V,247360540833645
Fessler25366054083336794120135170191
J,274660540832537
Bao280160540833669107
R,292760540833549
et299560540833456
al.30706054083324760
The314960540833372107
commensal327560540833168126184219257284317332
microbiome36266054083577310512616321406154083395594154190
is235161540831542
associated24146154083326087126160176208231265306
with27416154083526891130
anti-PD-128926154083337294110132170216241272
efficacy3186615408334537190123156189224
in343161540831554
metastatic350661540835894117151178202236258274307
melanoma214062540835893108141179217276308
patients.24696254083397294109144182204232245
Science27356254083326580115153186219
(80-29756254083195288112
).310762540831930
2018;359(6371):104-108.315762540833569101132144179213245264298332364396411423453484521544575607642656
doi:10.1126/science.aao3290.21406354083387692104134165178208236266300325349381396431469501535547581613651685717752787800
52.21406453085357085
Tanoue22386454083325997134172206
T,245764540833240
Morita251064540835391112128150182
S,270464540833245
Plichta2761645408335496495133154186
DR,29606454083448094
et306664540833355
al.31346454083314659
A3205645408340
defined32586454083377189105142177216
commensal348664540833167124181216253279312327
consortium39405540833167105132169191215231268325
elicits427855408334496496111134161
CD844525540834085119
T458555408332
cells463055408331648095121
and47645540833169108
anti-cancer4885554083316990106128161194231263297318
immunity.52165540831572129166204219241275285
Nature.551455408344763940654083215980113125
2019;565(7741):600-605.4078654083346799129141176210243261295329359389403415450485520544581616649661
doi:10.1038/s41586-019-0878-z.4752654083387591103132163176206237270304329353388418448481516540576608637661697732765798820847860
53.3940753085367186
Hegazy40407540834479119151181215
AN,4269754083418699
West43837540835790117140
NR,4538754083448094
Stubbington4647754083325391130170186224263285322361
MJT,50227540835580115124
et51607540833456
al.5231754083324760
Circulating5306754083395576107145160192214229267306
and39408540833270109
Tissue-Resident4069854083335076102140175198235270297312351385424445
CD4+45348540834086122166
T472085408333
Cells4773854083407489104130
With4924854083577396134
Reactivity50788540833671103135159174207223245279
to53778540832259
Intestinal54568540831553751081353940954083223876109125
Microbiota40869540835571103125163203219258280314
Are4421954083416398
Abundant45399540834282121160199232271293
in48539540831553
Healthy49279540834581113129152191222
Individuals5170954083155393109142158198236269284311
and55029540833271111
Function394010540833370108141165181220259
Is422010540831541
Altered42821054083415780114136170211
During451410540834584106122160200
Inflammation.4735105408315537188121179238271293309347386400
Gastroenterology.51561054083447710412815018722426228431834037839443339401154083387080
2017;153(5):1320-1337.e16.403211540833468100129139169198231249282301312342372404438462492522555587593627657688701
doi:10.1053/j.gastro.2017.07.047.47461154083377591103132163176206238272304328345357396428454477499536548584618649678684719752758793829860866
54.39401253085367388
Frankel40421254083325285123153187203
AE,42581254083417487
Coughlin435912540834077115154192207222260
LA,46321254083327589
Kim473412540833552109
J,485712540832436
et490612540833456
al.49761254083314760
Metagenomic504912540835490112145184219257295353368400
Shotgun546312540833270108130394013540833876113
Sequencing406613540833368107145179217249264302341
and442013540833270109
Unbiased454113540834482121136168195230269
Metabolomic482313540835489111144183222238276334349381
Profiling52171354083355593110127142157195234
Identify546413540831453881263940145408321365589
Specific404114540833270105137152169186217
Human427114540834380137169206
Gut449014540834380102
Microbiota460514540835368100120157196211248270302
and491914540833269107
Metabolites503914540835388110142180218234248270303330
Associated5381145408340689413116317820939401554083225595
with40521554083516789127
Immune419715540831472130168206241
Check-point445515540834078113146176196236275290328350
Therapy482215540833372107128161200232
Efficacy5071155408333516886118151183217
in530515540831553
Melanoma537515540835590106138176214394016540835790
Patients.40501654083356789104139177199226240
Neoplasia430716540834580118158174206233248280
(United460716540831963100115138172211
States).48391654083325386108142168186196
2017;19(10):848-855.505616540833468100129139169199219250282300312347383419442478512544556
doi:10.1016/j.neo.2017.08.004.39401754083387692104134165178208240272303328344357396431470482518552584613619655690703739775811823
55.39401853085367185
Payandeh40451854083356798131169208243281
Z,434618540833751
Yarahmadi44161854083366586119157215247286302
M,473718540835568
Nariman-Saleh-Fam48251854083457798114172204242264296329344379417440474503561
Z,540618540833751
et547618540833457
al.55521854083324760
Immune394019540831572130168206241
therapy41941954083216094116149188219
of442619540833756
melanoma:449519540835893108140178217275307319
Overview482719540834781115136171187221272
of511219540833857
therapeutic51821954083216095116149188223261283299331
vaccines.55261954083316439402054083316277115150177190
J4146205408324
Cell41852054083407490105
Physiol.430520540833573103130145183199212
2019;234(9):14612-14621.453220540833468100130143178213248268300318330360391427457487508539570606639670680
56.39402153085367288
Van404321540833667105
Hoecke416321540834483118151181215
L,439321540833245
Verbeke44532154083366990130165196230
R,469821540833549
Dewitte476221540834681132148170195228
H,500621540834457
et507821540833456
al.51492154083324760
mRNA522521540835793139180
in542021540831553
cancer54882154083316410239402254083316586
immunotherapy:404322540831573131168206244266305340361394433464478
beyond453822540833974106143182221
a4776225408332
source482522540832664102124155188
of503122540833756
antigen.51042254083327092107146181219232
Mol535322540835593109
Cancer.5479225408340731113940235408331658696
2021;20(1):48.405223540833468101132141176210229261275287322358371
57.39402453085367282
Pardi40432454083366890129144
N,420824540834659
Hogan428824540834584124157196
MJ,45052454083568294
Porter46202454083367496121155177
FW,481824540833393104
et494324540833457
al.50212454083324861
mRNA510324540835995142184
vaccines53082454083326699130146184220248
–5577245408335
a3940255408331
new398425540833771121
era41182554083335486
in421625540831552
vaccinology.42802554083326495126140177215230268306338347
Nat46402554083447697
Rev474925540833569101
Drug486225540834566104142
Discov.50162554083456086117153185194
2018;17(4):261279.52222554083346899129141170199215247264276310343372394026540833467100111
doi:40672654083387691104
10.1038/nrd.2017.243.41862654083346678109140173208233270291329342378412444473479515547580592
Epub479426540833271109149
2018495826540833468100131
Jan51042654083245795
12.52142654083346476
58.39402753085367187
Gjerstorff40392754083435893113140163199220242261
MF,43122754083548792
Kock441727540833471103133
K,456227540833549
Nielsen46242754083445993108134168206
O,484227540834757
et491227540833355
al.49802754083314659
MAGE-A1,505127540835496138171191232261270
GAGE533327540834485127160
and550527540833269108
NY-ESO-139402854083447997130163209232262
cancer/testis421428540833163100131164184207228261287309324349
antigen45752854083326989104142176213
expression480028540833364102123156182208222259297
during51092854083377494109146184
human530528540833773130161198
gonadal551528540833875394029540833870110142158
development.411829540833874106141156195235293328367389402
Hum454129540834482140
Reprod.470229540833570110132169209222
2007;22(4):953-960.494529540833468105138148183218235268286298333368401423458494530542
doi:55082954083387792104
10.1093/humrep/del494.39403054083346678109140176208233272309367388422461486522557573608641677689
Epub464430540833372110149
2007480930540833468104137
Jan49613054083245694
5.507130540833446
PMID:513230540833589104150163
17208940.53113054083346397131167201237273286
59.39403153085367084
Niemi40373154083456094152167
JVL,42173154083246194108
Sokolov433831540833271101138154192224
AV,45753154083417583
Schiöth467131540833365103118156178216
HB.49003154083448093
Neoantigen500631540834580118151189211226265300338
Vaccines;53573154083356698129144182217244256
Clinical39403254083395469106120152184199
Trials,4151325408332496496111136149
Classes,43123254083395486112138172198211
Indications,45353254083155290105136169190205242280306318
Adjuvants48653254083417993130162195232253280
and515732540833269107
Combinatorial5277325408339751331711862232552763133940335408321366884
Treatments.40393354083335084116137196231269290318332
Cancers438633540834073111143176198225
(Basel).46263354083195588114149165184195
2022;14(20):5163.483633540833569102136149179210229263297316328363394425459471
60.39403453085367388
Niemi40413454083456094152167
JVL,42213454083246194107
Sokolov434134540833270101138154192224
AV,45783454083417483
Schiöth467334540833365103118156177215
HB.49013454083448093
Neoantigen500734540834580118151189210225264299337
Vaccines;53573454083356698129144182217243255
Clinical39403554083395469106120152184199
Trials,4151355408332496496111136149
Classes,43123554083395486112138172198211
Indications,45353554083155290105136169190205242280306318
Adjuvants48653554083417993130162195232253280
and515735540833269107
Combinatorial5277355408339751331711862232552763133940365408321366884
Treatments.40393654083335084116137196231269290318332
Cancers438636540834073111143176198225
(Basel).46263654083195588114149165184195
2022;14(20):5163.483636540833569102136149179210229263297316328363394425459471
61.39403753085366981
Kyte40393754083356489123
JA,41803754083246478
Mu427637540835492
L,438637540833145
Aamdal444937540834174132171203218
S,468537540833345
et474837540833457
al.48233754083314760
Phase490137540833572104131166
I/II5085375408315405671
trial5174375408322435991106
of529837540833857
melanoma537337540835792108140178216394038540835789
therapy40423854083226095116148187219
with42733854083516689126
dendritic441238540833873111150171186209224256
cells4680385408331658095121
transfected48143854083224376114140160194226250284323
with51503854083516688126
autologous52893854083326992128144182221259297323
tumor-mRNA.394039540832260119158180200259295342383398
Cancer435939540834074112145179201
Gene458039540834480119154
Ther.475539540833373108130141
2006;13(10):905-918.491639540833569106142155185216234266298317329364401435458493525557571
doi:55073954083397893106
10.1038/sj.cgt.7700961.39404054083346678109140174208233258272285317355378391425460493529564600630639
Epub459540540833271109148
2006475940540833468104140
May491440540835587118
5.504740540833446
PMID:510940540833589104150163
16710345.52874054083346698131162195231264276
62.39404153085367389
Weide405041540835892108147183
B,425441540833649
Pascolo43244154083366996129166183222
S,456741540833346
Scheel463441540833366105141177193
B,484841540833649
et491841540833557
al.49964154083334962
Direct50794154083466284119152177
injection52774154083155369104138163178217256
of555441540833858
protamine-protected39404254083396097119152210225263298321361383420442476508532566606
mRNA:456042540835894139181194
results47694254083215582119134156184
of496842540833756
a5039425408332
phase508642540833877109136171
1/252714254083355691
vaccination5377425408332659712814318121339404354083223775114
trial4075435408321435991107
in420243540831553
metastatic427643540835793115148175198231253269301
melanoma459743540835893109142180218277310
patients.49274354083397294110145183205233246
J5194435408324
Immunother.523943540831573131169207246268306342363373
2009;32(5):498-507.394044540833468104140152187220237271289301335369404426460494527533
63.39404553085367287
Ping40494554083355088128
H,419845540834457
Yu427645540833571
W,436845540835767
Gong445645540834483122162
X,463945540833851
et471245540833456
al.47894554083324861
Analysis487145540834180112128160188203229
of512145540833857
melanoma519945540835893109142180219277310
tumor553045540832260394046540835796118
antigens40764654083327192108147182221248
and434246540833270110
immune447046540831573131169207243
subtypes473146540832664103126160200236263
for50124654083195779
the51094654083226096
development522346540833873106141157195235294329367389
of394047540833757
mRNA401847540835794140181
vaccine.42204754083326598129144183218231
Invest44724754083145384119146170
New466347540834480131
Drugs.481547540834668106146172186
2022;40(6):1173-1184.502247540833569102137150185221241275293306336364393428450481509541577590
doi:39404854083387691103
10.1007/s10637-022-01290-y.40564854083346678109140176208228253283314349383415433470503538558595626656690726749781791
Epub486048540833371109148
2022502148540833468101135
Aug516948540834178117
13.52994854083346376
Erratum53884854083325375108129167225
in:39404954083155365
Invest40214954083155385120147170
New420749540834581132
Drugs.435549540834567106145172186
2022455749540833469102137
Aug471049540834178118
27.48444954083346774
64.39405053085367489
Weber404450540835791130165187
JS,42455054083255769
Carlino43295054083407394110125163201
MS,454550540835487100
Khattak466050540833574107128153186216
A,489150540834155
et496150540833456
al.50325054083324760
Individualised51075054083155292107139155194231264279294320355395
neoantigen551750540833772394051540833770108130145184219257
therapy42185154083226095116149189220
mRNA-4157445851540835894140181203239270300333
(V940)48125154083185792127164182
plus50145154083395593119
pembrolizumab515351540833975133172194231247262291330388420459
versus39405254083326687115152178
pembrolizumab413952540833874132171193230246261290329387419458
monotherapy461852540835796134173195233268289322361393
in503152540831553
resected51045254083215582117150174208248
melanoma537252540835793108140179217394053540835790
(KEYNOTE-942):40505354083185388124170218251285306341377409427439
a4509535408332
randomised,45615354083215492131169227242268303343356
phase493753540833877109136171
2b512753540833573
study.52205354083264987126158168
Lancet.540853540833165103135169191204
2024394054540833468101133
Jan40885454083245795
18:S0140-6736(23)02268-7.41985454083346577111146178209245269306339373407426460495512547580615649684707738744
65.39405553085367388
Bafaloukos40495554083366989122138177216246284311
D,438155540834657
Gazouli445955540834477108145184200215
I,469555540831528
Koutserimpas474455540833573112135163198220236295334368395
C,516055540834053
et523455540833557
al.53125554083324861
Evolution539455540833365103120158181196394056540833776
and403256540833169108
Progress41565654083355693133154188215241
of441356540833757
mRNA448656540835793139180
Vaccines46825654083356799130145183218244
in494256540831553
the50115654083215994
Treatment51215654083335084116138196231269290
of542756540833757
Melanoma:55005654083548939405754083154785123182214226
Future41825754083326891129150184
Prospects.43815754083355693120159195227251279293
Vaccines46895754083366799130145183218245
(Basel).49495754083195487114149164184195
2023;11(3):636.515957540833468101136147178205220254271283318352387400
66.39405853085377693
Ralli40565854083367187103119
M,419958540835670
Botticelli42935854083367699125141175210227243259
A,457558540834358
Visconti46565854083375482116154195217234
IC,49135854083155872
et500858540833559
al.50905854083334963
Immunotherapy517758540831575135175214254278317354377411394059540834073
in404259540831555
the412659540832363100
Treatment42555954083345389123146207244284307
of459259540833859
Metastatic468059540835693117152180205240264280314
Melanoma:502359540835694111145185226287321335
Current538759540834179102126162202225
Knowledge394060540833473111161176210249287322
and427460540833169107
Future43936054083326890127148181
Directions.45866054083456081114146170185222260285299
J4897605408324
Immunol493360540831571128165203240256
Res.52016054083356995108
2020;2020.53226054083346799133145179213245278291
doi:10.1155/2020/9235638.39406154083387692104134165178208236266299322357391424458483517550585618652686720734
67.39406253085367179
Kitano40406254083355174107145183
S,424362540833346
Nakayama430962540834577107141172205262295
T,462462540833342
Yamashita468662540833565123155182219234257290
M.499662540835569
Biomarkers50856254083355189147179200231265286314
for54196254083185678
Immune551762540831573394063540835998137173
Check-point413563540834180116150182203244284301340362
Inhibitors45196354083155494110150167190228251279
in482063540831554
Melanoma.489663540835592108142181221281314328
Front52466354083335492132155
Oncol.542263540834889122160177190
2018;8(July):1-8.394064540833468100131143178197222260276307326338367386422435
doi:10.3389/fonc.2018.00270.43916454083387691104133165177213246280314338357395433465479515549580612625660696729762795808